NEW YORK – Invivoscribe announced Thursday that its test for FLT3 mutations in patients with leukemia has achieved regulatory compliance in the UK and Switzerland.
Invivoscribe Announces Registration of the LeukoStrat® CDx FLT3 Mutation Assay in the United Kingdom and Switzerland ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback